搜索临床试验以:LX7101 (0.25%)
总计2828个结果
-
Novartis Pharmaceuticals完全的
-
Sichuan Haisco Pharmaceutical Group Co., LtdSecond Affiliated Hospital, School of Medicine, Zhejiang University完全的
-
KBP BiosciencesWorldwide Clinical Trials完全的
-
Arcutis Biotherapeutics, Inc.完全的
-
Shanghai General Hospital, Shanghai Jiao Tong University...尚未招聘评估 AAV2-RPE65 基因治疗剂 (LX101) 在先天性黑蒙 (LCA) 患者中的扩展临床研究
-
Cara Therapeutics, Inc.终止
-
Cara Therapeutics, Inc.完全的
-
Innostellar Biotherapeutics Co.,Ltd主动,不招人
-
Institute of Medical Biology, Chinese Academy of...Hebei Provincial Center for Diseases Control and Prevention完全的
-
Novo Nordisk A/S完全的
-
Biomedical Advanced Research and Development AuthorityRho Federal Systems Division, Inc.; ICON plc招聘中
-
Gamaleya Research Institute of Epidemiology and...完全的
-
ReveraGen BioPharma, Inc.University of Pittsburgh; Cooperative International Neuromuscular Research Group完全的
-
St. Petersburg Research Institute of Vaccines and...完全的
-
ReveraGen BioPharma, Inc.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute... 和其他合作者完全的
-
University of California, San FranciscoBill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training Center, Bamako... 和其他合作者完全的
-
ReveraGen BioPharma, Inc.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute... 和其他合作者完全的
-
Galeno Desenvolvimento de Pesquisas ClínicasSocraTec R&D GmbH完全的